List of Excipients in Branded Drug ECONAZOLE NITRATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Trifluent Pharma LLC	ECONAZOLE NITRATE	econazole nitrate	73352-100	BUTANE
Trifluent Pharma LLC	ECONAZOLE NITRATE	econazole nitrate	73352-100	DIMETHICONE
Trifluent Pharma LLC	ECONAZOLE NITRATE	econazole nitrate	73352-100	GLYCERIN

Generic Drugs Containing ECONAZOLE NITRATE

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	econazole nitrate	21695-892	BENZOIC ACID
Rebel Distributors Corp	econazole nitrate	21695-892	BUTYLATED HYDROXYANISOLE
Rebel Distributors Corp	econazole nitrate	21695-892	MINERAL OIL

What are the Most Frequently-Used Excipients in ECONAZOLE NITRATE?

# Of NDCs	Excipient
5	APRICOT KERNEL OIL PEG-6 ESTERS
19	BENZOIC ACID
15	BUTYLATED HYDROXYANISOLE

Econazole Nitrate Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Econazole nitrate is an established topical imidazole antifungal with limited active-ingredient differentiation. Commercial value lies in formulation performance, patient adherence, preservative strategy, delivery format, manufacturing efficiency, and targeted indications. The leading development opportunities are low-irritancy creams, rapidly drying foams, sprayable systems, pediatric-friendly formulations, and products designed for high-moisture or intertriginous skin sites.

What is econazole nitrate and how is it marketed?

Econazole nitrate is a synthetic imidazole antifungal used to treat dermatophyte and yeast infections, including tinea pedis, tinea cruris, tinea corporis, cutaneous candidiasis, and pityriasis versicolor. The active ingredient inhibits fungal ergosterol biosynthesis by interfering with lanosterol 14-alpha-demethylase.

In the United States, econazole nitrate is primarily marketed as a prescription topical product. The main dosage forms are:

Product type	Strength	Typical use	Regulatory position
Cream	1% econazole nitrate	Dermatophyte and yeast skin infections	Generic and branded prescription products
Foam	1% econazole nitrate	Interdigital tinea pedis	NDA product and potential generic target
Other topical formats	Not broadly established in the U.S.	Potential reformulation opportunities	Requires separate regulatory strategy

The cream market is mature and price competitive. The foam format has greater formulation and device complexity, which can create higher barriers to entry and stronger differentiation.

FDA-approved econazole products include econazole nitrate cream 1% and Ecoza topical foam 1%. The cream label covers several superficial fungal infections, while Ecoza was approved for interdigital tinea pedis in patients aged 12 years and older.[1,2]

What excipients are used in approved econazole nitrate products?

Approved econazole products use different excipient platforms because the commercial objectives of a cream and foam differ.

Econazole nitrate cream excipients

Representative econazole nitrate cream formulations use a semisolid oil-in-water or emulsion-based vehicle. Public product labeling identifies excipients such as:

• Benzoic acid
• Butylated hydroxyanisole
• Mineral oil
• Polyethylene glycol 400 monostearate
• Purified water
• Sodium hydroxide
• Stearyl alcohol

The exact inactive-ingredient profile can differ between manufacturers and approved generic products. Excipient selection affects particle wetting, drug distribution, preservative performance, spreadability, skin feel, and storage stability.

The main technical constraint is econazole nitrate’s limited aqueous solubility. A formulation must prevent recrystallization while maintaining uniform drug content during manufacturing and shelf life. The formulation also must avoid excessive alkalinity because pH changes can affect skin tolerability and drug solubility.

Econazole nitrate foam excipients

Ecoza foam uses a different platform. The labeled inactive ingredients include:

• Cetyl alcohol
• Citric acid
• Diethylene glycol monoethyl ether
• Polysorbate 60
• Potassium sorbate
• Purified water
• Stearyl alcohol

The foam system is designed for rapid application to interdigital spaces. Diethylene glycol monoethyl ether acts as a solvent and penetration-enhancing vehicle. Fatty alcohols contribute to foam structure and emulsion consistency. Polysorbate 60 supports dispersion and emulsion stability, while potassium sorbate provides antimicrobial preservation under appropriate pH conditions.[2]

Which excipient strategies can improve econazole nitrate products?

The strongest opportunities involve performance improvements that can be measured in comparative development studies.

1. Solubilization and recrystallization control

Econazole nitrate can be formulated using solvent systems, cosolvents, surfactants, or lipid vehicles that improve drug distribution. Useful approaches include:

• Glycol ethers
• Polyethylene glycol derivatives
• Medium-chain triglycerides
• Isopropyl myristate
• Nonionic surfactants
• Phospholipid or lipid-based systems
• Amorphous solid dispersions in selected topical vehicles

The commercial objective is not simply to maximize solubility. Excessive solvent loading can increase irritation, drying, odor, or volatility. The preferred system maintains a stable, evenly distributed drug phase while producing acceptable sensory properties.

2. Lower-irritancy preservation

Traditional preservatives and acidic systems can cause irritation in fissured or inflamed skin. Potential strategies include:

• Low-level organic acid preservation
• Potassium sorbate or sorbic acid systems
• Reduced-water or water-activity-controlled formulations
• Single-use packaging
• Airless pumps that reduce contamination
• Preservative-free unit-dose formats

Preservative reduction is commercially attractive for pediatric, geriatric, and sensitive-skin applications. It increases microbiological-control requirements and may raise packaging costs.

3. Improved skin feel

Many topical antifungal products are rejected by patients because they are greasy, sticky, slow to dry, or difficult to apply between toes. Excipient selection can create differentiation through:

• Fast-break emulsions
• Non-greasy esters
• Volatile solvents
• Low-residue gels
• Silicone-containing vehicles
• Lightweight foams
• Sprayable solutions

A formulation with a shorter drying time can be positioned for athletes, workers wearing occlusive footwear, and patients with interdigital infections.

4. Moisture management

Intertriginous and interdigital infections occur in environments with heat, moisture, friction, and occlusion. A successful vehicle should deliver econazole nitrate while limiting prolonged wetness.

Potential design directions include:

• Water-reduced creams
• Absorbent powder-cream hybrids
• Foams with rapid solvent evaporation
• Barrier-forming systems
• Hydrophobic films that reduce water exposure
• Vehicles with controlled residence time

Barrier systems must be developed carefully. Excessive occlusion may increase local hydration and potentially worsen maceration.

5. Adhesion and residence time

A topical formulation must remain at the application site long enough to support effective treatment. Mucoadhesive or bioadhesive polymers can improve residence time, particularly for genital, perianal, or difficult-to-access skin sites.

Candidate materials include carbomers, cellulose derivatives, polyacrylates, and selected natural polymers. The commercial advantage is strongest when a product reduces application frequency or improves persistence after washing. Any change in dosing frequency would require clinical and regulatory support rather than relying only on in vitro testing.

What formulations are commercially attractive for econazole nitrate?

Creams

Creams have the lowest technical barrier and the largest generic market. Opportunities include:

• Non-greasy cream
• Low-odor cream
• Rapidly absorbed emulsion
• Sensitive-skin cream
• Pediatric-friendly cream
• Airless-pump packaging
• Unit-dose sachets for adherence and hygiene

Cream products face intense price competition. Formulation differentiation must be paired with manufacturing cost control, reliable supply, and a clear channel strategy.

Foams

Foam is the most defensible established format. It provides fast application and may be preferred for interdigital disease. Development challenges include:

• Foam collapse during storage
• Dose reproducibility
• Container compatibility
• Valve performance
• Flammability or solvent handling
• Cold-temperature behavior
• Residual solvent odor
• Microbiological control

A generic foam may face more complex bioequivalence requirements than a conventional cream. FDA topical-product guidance emphasizes comparative quality, product performance, and, where applicable, pharmacodynamic or clinical evidence.[3]

Gels and solutions

Gels and solutions could offer rapid drying and lower residue. Their limitations include:

• Increased stinging on fissured skin
• Lower residence time
• Potential crystallization
• Higher solvent exposure
• Greater flammability risk for volatile systems

These formats are more suitable for selected body sites than for broad use on inflamed skin.

Sprays

Sprays could improve access to the feet and large body areas. Commercial advantages include reduced hand contact and improved convenience. Development risks include:

• Dose uniformity across spray angles
• Aerosol or pump compatibility
• Inhalation exposure
• Flammability
• Overspray and environmental loss
• Requirements for container-closure performance

A non-aerosol pump spray is generally less complex than a pressurized aerosol but still requires robust delivered-dose testing.

Nail and keratin-penetrating products

Onychomycosis is a large market, but econazole nitrate is not automatically interchangeable with products specifically developed for nail penetration. A nail lacquer, film-forming solution, or penetration-enhanced system would likely require substantial clinical support.

Potential excipient tools include film-forming polymers, keratin-wetting solvents, penetration enhancers, and volatile carriers. The product would compete with established agents such as ciclopirox, efinaconazole, and tavaborole. The opportunity is commercially meaningful but technically and clinically demanding.

How does econazole nitrate compare with competing topical antifungals?

Active ingredient	Common dosage forms	Main commercial position	Excipient opportunity
Econazole nitrate	Cream, foam	Broad superficial fungal infections; differentiated foam	Improved drying, skin feel, and foam delivery
Clotrimazole	Cream, solution, vaginal products	High-volume generic and OTC markets in many countries	Low-cost, patient-friendly vehicles
Miconazole nitrate	Cream, powder, spray, vaginal products	Broad dermatology and gynecology presence	Powder-cream and moisture-control systems
Ketoconazole	Cream, shampoo, foam	Dermatology and seborrheic dermatitis	Shampoo, foam, and scalp delivery
Terbinafine	Cream, gel, spray, solution	Strong dermatophyte positioning and rapid-course products	Fast-drying and low-residue systems
Ciclopirox	Cream, gel, shampoo, lacquer	Dermatology and nail products	Film-forming and keratin delivery
Efinaconazole	Topical solution	Prescription onychomycosis product	Penetration and brush-delivery systems

Econazole’s advantage is broad antifungal activity and established clinical use. Its disadvantage is the absence of a large, differentiated consumer brand in the U.S. market. Excipient innovation must therefore create a practical benefit, not merely a novel inactive-ingredient list.

What regulatory pathway applies to new econazole nitrate formulations?

A new econazole nitrate topical product generally would be regulated as a prescription drug unless it qualifies under an applicable over-the-counter monograph or other FDA pathway. U.S. generic products may use an abbreviated new drug application when they meet the relevant requirements for sameness, quality, strength, dosage form, route, and bioequivalence.

The regulatory burden depends on the proposed change:

Development approach	Likely regulatory burden
Same cream dosage form with equivalent composition	ANDA-focused development
Different excipient system in a cream	Comparative quality and bioequivalence analysis
Foam generic	Device, container, performance, and bioequivalence requirements
New indication	Clinical development and labeling support
New dosing frequency	Clinical evidence likely required
New nail or mucosal product	Product-specific clinical and safety program

The inactive ingredients must be justified for safety, quality, and performance. FDA’s inactive-ingredient database can support precedent analysis, but prior use in another product does not eliminate the need for formulation-specific evaluation.[4]

What patents protect econazole nitrate products?

Econazole nitrate itself is an old active ingredient, and composition-of-matter exclusivity is not a current commercial barrier in the United States. The relevant protection areas are more likely to involve:

• Foam vehicles
• Solvent and surfactant combinations
• Container and valve systems
• Specific particle-size or crystal forms
• Combination products
• Dosing regimens
• New indications
• Manufacturing processes

The Orange Book status must be evaluated separately for each reference product and NDA. Generic econazole nitrate cream products are generally exposed to price competition because the active ingredient is off patent. A branded foam may have greater protection through formulation, device, or method-of-use claims, although patent listings and enforceability must be reviewed against current FDA Orange Book records and USPTO prosecution histories.[5,6]

Publicly available product information does not support treating econazole nitrate as a biologic or biosimilar opportunity. Biosimilar risk is therefore not applicable. The competitive threat comes from generic topical antifungals, authorized generics, alternative dosage forms, and low-cost international suppliers.

When does econazole nitrate lose exclusivity?

Econazole nitrate has already lost active-ingredient exclusivity in the United States. The commercially relevant exclusivity question concerns individual products rather than the molecule.

A cream manufacturer generally faces immediate generic competition if it enters an established market. A foam manufacturer may obtain a longer commercial window if it owns defensible formulation or device claims and has a product-specific regulatory advantage.

Potential generic launch scenarios include:

1. A low-cost cream launch competing primarily on price.
2. A differentiated cream launch using improved sensory properties.
3. A foam launch after resolving formulation and device requirements.
4. An authorized generic or private-label supply agreement.
5. A regional launch using country-specific registration and local manufacturing.

Paragraph IV litigation is more relevant to a branded NDA foam or a later innovative formulation than to conventional econazole nitrate cream. A generic applicant would need to assess listed patents, exclusivity codes, certification strategy, and any litigation stay before launch. No biosimilar pathway applies.

Which companies are positioned to compete in econazole nitrate?

Competition is fragmented across generic manufacturers, dermatology companies, contract manufacturers, and specialty topical developers. Likely commercial participants include:

• Generic pharmaceutical companies with topical manufacturing capacity
• Specialty dermatology companies
• Contract development and manufacturing organizations
• Private-label pharmacy suppliers
• Regional distributors in markets where topical antifungals are sold without prescription

The most attractive licensing targets are companies with:

• FDA-approved topical manufacturing sites
• Foam-filling and valve-assembly capabilities
• Dermatology sales channels
• Established pharmacy distribution
• Experience with ANDA topical products
• Proprietary packaging or delivery systems

A licensing deal would be most defensible where one party contributes the formulation and regulatory package while another contributes manufacturing scale and commercial distribution.

What manufacturing and intellectual-property barriers exist?

The active ingredient is relatively accessible. The more significant barriers are process control and product performance.

Key manufacturing risks include:

• Uniform dispersion of econazole nitrate
• Control of particle size and polymorphic behavior
• Emulsion inversion or phase separation
• Foam density and collapse
• Solvent evaporation during filling
• Microbial contamination
• Container-closure interaction
• Preservative failure
• Scale-up changes in mixing energy and shear

Manufacturing know-how can provide practical protection even where patent protection is limited. A robust process should define critical material attributes, including active-particle characteristics, solvent quality, surfactant grade, water quality, and fatty-alcohol composition.

What is the commercial opportunity for excipient innovation?

The highest-value opportunity is a product that improves adherence without materially increasing manufacturing cost. The strongest candidates are:

Opportunity	Commercial rationale	Development risk
Fast-drying cream	Better patient acceptance for feet and groin	Moderate
Low-irritancy cream	Sensitive-skin and pediatric positioning	Moderate
Econazole foam generic	More differentiated dosage form	High
Moisture-control formulation	Interdigital and intertriginous use	Moderate
Pump spray	Convenience and reduced hand contact	Moderate to high
Unit-dose preservative-reduced product	Hygiene and tolerability	High
Nail formulation	Access to a larger, higher-value market	High
Combination antifungal-barrier product	Differentiated skin-care positioning	High

Revenue exposure is greatest in products with broader distribution, repeat use, and prescription reimbursement. Creams provide volume but limited margins. Foams, nail products, and proprietary delivery systems provide better margin potential but require greater investment and regulatory support.

Key Takeaways

• Econazole nitrate is an off-patent topical antifungal with established prescription use.
• Conventional cream products are commercially accessible but face strong generic price pressure.
• Foam is the most attractive established differentiated dosage form.
• Solubilization, recrystallization control, preservation, drying time, and skin feel are the primary excipient development variables.
• A formulation change can create commercial value only if it improves adherence, tolerability, delivery, or manufacturing economics.
• Patent value is more likely to arise from formulation, device, process, or method-of-use claims than from the active ingredient.
• Biosimilar competition is irrelevant because econazole nitrate is a small-molecule drug.
• The strongest near-term opportunities are fast-drying creams, low-irritancy systems, moisture-control vehicles, and foam products.
• Nail delivery and combination products offer larger strategic upside but carry substantially higher clinical and regulatory risk.

FAQs

Is econazole nitrate suitable for an OTC formulation?

Econazole nitrate has prescription positioning in the United States. An OTC product would require an applicable FDA monograph pathway or a separate regulatory submission supporting nonprescription use.

Which excipient is most important for econazole nitrate solubility?

The solvent and cosolvent system is usually the central variable, but solubility must be balanced against crystallization, irritation, evaporation, and skin feel. A solvent that performs well in vitro may not produce the best commercial product.

Can econazole nitrate be formulated as a transdermal patch?

A conventional transdermal patch is commercially unattractive for superficial fungal infections because treatment is local rather than systemic. A localized adhesive film may be more practical for selected lesions but would require product-specific performance and safety data.

Does econazole nitrate have a meaningful pediatric formulation opportunity?

Yes. A low-irritancy, low-odor, easy-spread cream or foam could improve pediatric usability. The product would need age-appropriate safety support and careful control of solvents, preservatives, fragrance, and accidental exposure risk.

Can an econazole nitrate product be protected without a composition patent?

Yes. Commercial protection may derive from formulation claims, manufacturing processes, container-closure systems, dosing regimens, clinical indications, regulatory exclusivity, trade secrets, and distribution agreements. These protections are generally narrower and more vulnerable than composition-of-matter patents.

References

1. U.S. Food and Drug Administration. (n.d.). Econazole nitrate cream, 1%: Prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Ecoza (econazole nitrate) topical foam, 1%: Prescribing information. DailyMed.

3. U.S. Food and Drug Administration. (2022). Physicochemical and structural (Q3) characterization of topical drug products submitted in ANDAs: Draft guidance for industry. FDA.

4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

6. United States Patent and Trademark Office. (n.d.). Patent Center. USPTO.